Straits Times Index
3,193.66 +38.97 (+1.24%) Nikkei
38,164.24 +202.44 (+0.53%) Hang Seng
16,469.29 +217.45 (+1.34%) FTSE 100
7,847.99 +27.63 (+0.35%) Bitcoin USD
61,913.78 -2,227.00 (-3.47%) CMC Crypto 200
885.54 0.00 (0.00%)
Ultimovacs ASA (ULTI.OL)
| Previous close | 10.10 |
| Open | 9.90 |
| Bid | 8.50 x N/A |
| Ask | 8.85 x N/A |
| Day's range | 8.60 - 10.00 |
| 52-week range | 6.07 - 178.60 |
| Volume | |
| Avg. volume | 1,476,593 |
| Market cap | 347.501M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.77 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 79.50 |
GlobeNewswireUltimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan
- GlobeNewswire
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
Oslo, April 15, 2024: In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, 2024, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based voting rights without voting instructions for 9,063,854 shares, representing 26.34% of the total voting rights in the company. The proxies are only valid for the Annual General Meeting on April 18, 2024. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegi
- GlobeNewswire
Ultimovacs – Invitation to Business Update on April 17, 2024
NON-REGULATORY PRESS RELEASE Oslo, April 9, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company will host a webcast on April 17, 2024, at 11:00. Ultimovacs’ management will provide a company update emphasizing recent developments and the future potential within the clinical program. The presentation will be followed by a Q&A session. Date: We
